Core Insights - Tongrentang reported a revenue of 18.597 billion yuan for 2024, a year-on-year increase of 4.12%, while net profit attributable to shareholders decreased by 8.54% to 1.526 billion yuan [1] - The company experienced significant growth in its core business, particularly in cardiovascular products and tonics, with revenues of 5.146 billion yuan and 2.127 billion yuan respectively, reflecting year-on-year increases of 17.26% and 22.98% [1] - The company has increased its self-operated pharmacy count by 250 to a total of 1,251, showing a notable improvement compared to previous years [1] Financial Performance - In Q4 2024, Tongrentang achieved a revenue of 4.778 billion yuan, a year-on-year increase of 15.41%, but net profit fell by 36.65% to 176 million yuan [1] - The company's gross margin for cardiovascular products decreased by 8.31 percentage points to 49.31%, marking the first time it has fallen below 50% in five years, primarily due to rising raw material costs [2] - The company plans to increase cash dividends to 1.371 billion yuan, representing 89.86% of the net profit attributable to shareholders, indicating a commitment to shareholder returns despite declining profits [3] Future Outlook - The gross margin pressure is expected to improve by 2025 due to potential cost relief from imported raw materials and possible price adjustments for key products [2] - The company maintains a "buy" rating, with projected net profits of 1.815 billion yuan, 2.102 billion yuan, and 2.429 billion yuan for 2025-2027, reflecting year-on-year growth rates of 18.90%, 15.84%, and 15.55% respectively [3]